Nkarta Reveals FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease; Option To Redose Patients Granted In Both Ntrust-1 And Ntrust-2 Studies; Rheumatoid Arthritis Cohort To Be Added To Ntrust-2